News for MBIO Stock

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement Mustang Bio Announces Sale of Fixed Assets and Exit of Facility Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement Mustang Bio Announces Closing of $8 Million Public Offering Mustang Bio Announces Pricing of $8 Million Public Offering Mustang Bio Announces Reverse Stock Split Mustang Bio Receives Positive Listing Determination from Nasdaq Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy Mustang Bio Announces Closing of $4 Million Public Offering Mustang Bio Announces Pricing of $4 Million Public Offering Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma Mustang Bio to Participate in Upcoming September 2023 Investor Conferences Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Mustang Bio to Participate in Two August 2023 Investor Conferences Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences Mustang Bio Announces Participation in Upcoming Scientific Meetings Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy Mustang Bio Announces Reverse Stock Split Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Mustang Bio to Participate in Upcoming September 2022 Investor Conferences Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Mustang Bio to Participate in Three March 2022 Investor Conferences Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences Mustang Bio Added to the NASDAQ Biotechnology Index Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences Mustang Bio to Participate in Three September 2021 Investor Conferences Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive Mustang Bio to Present at the Raymond James Human Health Innovation Conference Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020 Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy) Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Mustang Bio Announces Proposed Public Offering of Common Stock Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights Mustang Bio to Host Virtual Annual Meeting of Stockholders